Prosetta Antiviral Inc Enters into Multi-year Antiviral Drug Development Collaboration with Bristol-Myers Squibb

Prosetta Antiviral Inc today announced the execution of a strategic alliance with Bristol-Myers Squibb Company BMY to further discover and develop select drug candidates representing new, novel classes of antiviral drugs. Prosetta currently has a portfolio comprising novel chemical classes of small molecules with robust antiviral activity which target catalytic host protein interactions essential for the virus, but not the host. These molecules represent a new therapeutic approach for antiviral agents. The collaboration will include a research program focused on the discovery and advancement of compounds shown to block viral capsid assembly using Prosetta's proprietary drug discovery platform. Bristol-Myers Squibb will have the right to develop and commercialize products arising from the research program.